Virios Therapeutics Long Term Debt

Virios Therapeutics posts a long-term debt of $70K as of June 2026. That compares with $130M in the prior-year period — down 99.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Virios Therapeutics's long-term debt was $130M. The latest reading is $70K — a 99.9% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Virios Therapeutics's financial statement story. At $70K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for VIRI's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Virios Therapeutics's other metric pages and overview cover the third.

Judging Virios Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $70K here, then scan peer and history charts to see if the gap is persistent.